Alzamend Neuro reported a net loss of USD 2.2 million for Q3 ended Jan. 31, with a loss from operations of USD 2.2 million. Research and development expense rose 189% to USD 1.28 million, driven by higher clinical trial fees related to the AL001 Phase IIB healthy-subject study conducted with Massachusetts General Hospital. General and administrative expense increased 56% to USD 0.92 million, mainly due to higher legal fees tied to litigation following termination of the ALZN002 clinical trial. The company reported no revenue for the quarter and said it expects to report topline data in Q1 2026 from the completed clinical portion of its Phase II study of AL001 in healthy subjects.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001214659-26-003166), on March 11, 2026, and is solely responsible for the information contained therein.